Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
Sponsor: Alnylam Pharmaceuticals
Summary
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
93
Start Date
2026-04-27
Completion Date
2028-10-01
Last Updated
2026-05-14
Healthy Volunteers
No
Conditions
Interventions
ALN-AGT01 RVR
ALN-AGT01 RVR will be administered subcutaneously (SC)
Placebo
Placebo will be administered SC
Zilebesiran
Zilebesiran will be administered SC
Locations (3)
Clinical Trial Site
Lake Forest, California, United States
Clinical Trial Site
Tampa, Florida, United States
Clinical Trial Site
Savannah, Georgia, United States